7 results
DEFM14A
LABP
Landos Biopharma Inc
25 Apr 24
Proxy related to merger
5:07pm
3.27 of the Company Disclosure Schedule sets forth an accurate and complete list of (i) each supplier who was one (1) of the ten (10) largest suppliers … of this Agreement and (ii) each supplier materially involved in the conduct of any clinical trials operated by the Company or any of its Subsidiaries
PREM14A
LABP
Landos Biopharma Inc
15 Apr 24
Preliminary proxy related to merger
5:18pm
.
Section 3.27 Major Suppliers. Section 3.27 of the Company Disclosure Schedule sets forth an accurate and complete list of (i) each supplier who … or payable to such suppliers as of the date of this Agreement and (ii) each supplier materially involved in the conduct of any clinical trials operated
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
9:19am
Disclosure Schedule sets forth an accurate and complete list of (i) each supplier who was one (1) of the ten (10) largest suppliers of the Company and its … ) each supplier materially involved in the conduct of any clinical trials operated by the Company or any of its Subsidiaries as of the Effective Time
8-K
EX-2.1
LABP
Landos Biopharma Inc
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
an accurate and complete list of (i) each supplier who was one (1) of the ten (10) largest suppliers of the Company and its Subsidiaries (taken as a whole … ) for each of 2022 and 2023, based on amounts paid or payable to such suppliers as of the date of this Agreement and (ii) each supplier materially involved
S-1
EX-10.1
ub7utlxq11gzl1
13 Jan 21
IPO registration
5:07pm
DRS/A
EX-10.1
hc8mfnz0u
1 Dec 20
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next